Kengreal Injection, Powder, Lyophilized, For Solution
Product Images NDC 10122-620

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Kengreal (NDC 10122-620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chiesi Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Bleeding Results In The Champion Phoenix Studya (all Non-cabg Related) (Kengreal 1)

Figure 1: Bleeding Results In The Champion Phoenix Studya (all Non-cabg Related) (Kengreal 1)
FDA Label Image

Chemical Structure (Kengreal 2)

Chemical Structure (Kengreal 2)
FDA Label Image

Figure 2: Cangrelor Pd Characteristics (Kengreal 3)

Figure 2: Cangrelor Pd Characteristics (Kengreal 3)
FDA Label Image

Figure 3: Inhibition (mean) Of 20 µm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Cangrelor 30 Mcg/kg Bolus And 120-minute 4 Mcg/kg Infusion With Transition To Other Oral P2y12 Platelet Inhibitors. (Kengreal 4)

Figure 3: Inhibition (mean) Of 20 µm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Cangrelor 30 Mcg/kg Bolus And 120-minute 4 Mcg/kg Infusion With Transition To Other Oral P2y12 Platelet Inhibitors. (Kengreal 4)
This appears to be a table showing a comparison of various antiplatelet drugs such as Ticagrelor, Prasugrel, and Clopidogrel in relation to Cangrelor Infusion. It also displays the relationship between Cangrelor and each of the drugs listed, indicating which drug is more effective at various dosage levels. The table also includes a timeline represented in hours.*
FDA Label Image

Figure 4: Champion Phoenix Study: Primary Efficacy Endpoint By Subgroup (mitt Populationa) (Kengreal 5)

Figure 4: Champion Phoenix Study: Primary Efficacy Endpoint By Subgroup (mitt Populationa) (Kengreal 5)
FDA Label Image

Kengreal (cangrelor) For Injection 50 mg Vial Carton (Kengreal 6)

Kengreal (cangrelor) For Injection 50 mg Vial Carton (Kengreal 6)
This is a pharmaceutical label for a medication called Kengreal. It is available in a pack of 10 and contains 50mg of cangrelor, which is administered via injection. The label also includes some manufacturing information and storage instructions for the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.